Candel Slides 26% After Mid-2027 BLA Plan and New $50M Stock Program
Candel said it plans to file its prostate cancer application in mid-2027 and set up a new $50 million at-the-market stock program. Shares closed Nov. 13 at $6.20, 26.1% below the Nov. 12 close.





